Invest Clin 63(1): 57 - 69, 2022 https://doi.org/10.54817/IC.v63n1a05
Corresponding author: Alexis Rodríguez-Acosta. Instituto Anatómico, Ciudad Universitaria de Caracas, Universidad
Central de Venezuela, Caracas 1041. Email: rodriguezacosta1946@yahoo.es
A new approach of immunotherapy against
Crotalus snakes envenoming: ostrich
(Struthio camelus) egg yolk antibodies
(IgY-technology).
Carlos Bello1, Fátima Torrico1, Juan C. Jiménez1,2, Mariana V. Cepeda1,
Miguel A. López1 and Alexis Rodríguez-Acosta1,3
1Biotecfar C.A, Facultad de Farmacia, Universidad Central de Venezuela, Caracas,
República Bolivariana de Venezuela.
2Instituto de Inmunología, Facultad de Medicina, Universidad Central de Venezuela,
Caracas, República Bolivariana de Venezuela.
3Laboratorio de Inmunoquímica y Ultraestructura, Instituto Anatómico, Universidad
Central de Venezuela, Caracas, República Bolivariana de Venezuela.
Key words: antivenom; Crotalus snakes; ostrich egg yolk; IgY; Struthio camelus; venom.
Abstract. Crotalid envenomation is a neglected collective health problem
involving many countries in America, which need secure and inexpensive snake
anti-venom treatments. Here, high antibody titers (IgY) were raised in the Os-
trich (Struthio camelus) egg yolk by immunizing with the venom of Venezuelan
venomous Crotalus snakes. Ostriches were immunized with a pool of venoms
from common rattlesnake (Crotalus durissus cumanensis), Uracoan rattle-
snake (Crotalus vegrandis), Guayana rattlesnake (Crotalus durissus ruruima)
and black rattlesnake (Crotalus pifanorum). The anti-snake venom antibodies
were prepared from egg yolk by the water dilution method, enriched by the ad-
dition of caprylic acid (CA) and precipitation with ammonium sulfate at 30%
(W/V). The purity and molecular mass of the final product was satisfactory,
yielding a single 175 kDa band in SDS-PAGE gels ran under non-reducing
conditions. In the immunoblot analysis, specific binding of the antivenom was
observed with most venom proteins. The LD50 was 16.5 g/mouse (825 µg/kg
body weight). High titers of IgY against Crot/pool venom were shown by ELISA.
The median effective dose (ED50) was 19.66 mg/2LD50. IgY antibodies neutral-
ized efficiently the Crot/pool venom lethality. As far as we know, this is the first
anti-snake venom produced in ostriches, which could make this technology an
affordable alternative for low-income countries, since it is likely to produce
58 Bello et al.
Investigación Clínica 63(1): 2022
Un nuevo enfoque de inmunoterapia contra el envenenamiento
de serpientes Crotalus: anticuerpos de yema de huevo de
avestruz (Struthio camelus) (tecnología IgY).
Invest Clin 2022; 63 (1): 57 – 69
Palabras clave: antiveneno; avestruz Crotalus; IgY; Struthio camelus; veneno.
Resumen. El envenenamiento por crotálidos es un problema de salud
colectiva desatendido, que involucra a muchos países del continente ameri-
cano, los cuales necesitan tratamientos seguros y económicos. En este tra-
bajo, se obtuvieron títulos altos de anticuerpos (IgY) producidos en yema
de huevo de avestruz (Struthio camelus) mediante la inmunización con
el veneno de serpientes venezolanas del genero Crotalus. Se inmunizaron
avestruces con una colección de veneno de serpientes de cascabel común
(Crotalus durissus cumanensis), cascabel de Uracoa (Crotalus vegrandis),
cascabel de Guayana (Crotalus durissus ruruima) y cascabel negra (Crota-
lus pifanorum). Los anticuerpos anti-veneno de serpiente se prepararon a
partir de yema de huevo por el método de dilución en agua, enriquecidos
mediante la adición de ácido caprílico (CA), seguido de una precipitación
con sulfato de amonio al 30% (P/V). La pureza y masa molecular de los
anticuerpos (IgY) se definieron mediante ensayos de SDS-PAGE nativos y
las masas moleculares se establecieron electroforéticamente, obteniéndose
una única banda de IgY de 175 kDa. El análisis de inmunotransferencia
mostró la unión específica del antiveneno con la mayoría de las proteínas
del veneno. La DL50 fue de 16,5 µg/ratón (825 µg / kg de peso corporal);
Se mostraron títulos altos de IgY contra el veneno de Crot / pool median-
te ELISA. La dosis mediana efectiva (DE50) fue de 19,66 mg/2 LD50. Los
anticuerpos IgY neutralizaron eficazmente la letalidad del veneno de Crot
/ pool. Hasta donde sabemos, se trata del primer antídoto de serpiente
producido en avestruces, lo que podría abaratar la producción de este tra-
tamiento en países del tercer mundo. Ya que es probable que se obtengan
alrededor de 2-4 g de IgY por huevo de avestruz. Por lo tanto, se podrían
purificar casi 400 g de IgY de un solo avestruz durante un año. Asimismo,
debido a las enormes diferencias en el costo de inversión en el manteni-
about 2-4 g of IgY per ostrich egg. Hence, almost 400 g of IgY can be purified
from only one ostrich during a year. In addition, there are enormous differences
in the cost of investment in the maintenance of horses, from the points of view
of infrastructure, feeding and veterinary care, in which the cost can reach USD
100 per animal per day, compared to a maintenance cost of USD 146 per month
per producing bird. These results are encouraging and could easily be extrapo-
lated to the manufacturing of other antivenoms and antitoxins as well, as they
could be applied to the manufacturing of potential diagnostic tools.
Crotalus snakes envenoming treated with ostrich (Struthio camelus) IgY 59
Vol. 63(1): 57 - 69, 2022
INTRODUCTION
Venomous snakebite is a worldwide
problem, especially in tropical and subtropi-
cal geographical regions. There are more
than five million snakebite accidents annual-
ly worldwide; the members of the Viperidae
family 1 produce the most common snake-
bites that take place in the American conti-
nent (~ 98%).
Traditional antivenom production
is based on purified antibodies extracted
from hyperimmunized horses’ plasma 2. In
recent years, several authors report that
bird’s (mainly chicken) antibodies produced
against snake venoms, presented venom
effective neutralization activities 2,3. How-
ever, despite their potential considering
their body size and egg-laying advantages,
ostriches (Struthio camelus) have not been
previously tested for snake anti-venom pro-
duction. Clinical assays will be need to as-
sess their security as an antidote to human
victims of ophitoxemia and further experi-
mentation addressing IgY-based antivenoms
safety and effectiveness is required.
MATERIALS AND METHODS
Reagents
Polyvalent anti-ophidic serum (PAOS)
(Biotecfar C.A, Universidad Central de Vene-
zuela, Pharmacy Faculty, Caracas, República
Bolivariana de Venezuela). Sodium chloride,
sodium citrate, sodium azide, tris, hydro-
chloric acid, sodium hydroxide, Coomassie
blue, acrylamide, bis-acrylamide, ammoni-
um per-sulphate, glacial acetic acid, temed,
glycerol, sodium bicarbonate, caprylic acid
(Sigma-Aldrich, Missouri, USA). Saran wrap
(S.C. Johnson & Son, Inc, USA). Complete
Freund’s and incomplete Freund’s adjuvants
(GIBCO, USA). Antibody goat anti-avian (in-
cluded anti-ostrich) (Laboratories ABCAM,
USA). Peroxidase substrate (TMB)(Vector
Lab, USA). 30 kDa cassette filtration unit
(Vivaflow 50 R, Sartorius, Germany). Fil-
ter (Sartorious Laboratories, Germany).
Microtitration plates (Corning® ELISA mi-
croplates, USA). Automatic ELISA reader
(Bio-Tek Laboratories, USA). Mini-Protean
II system (Bio-Rad Laboratories, USA).
Trans Blot SD system (Bio-Rad Laboratories,
USA). Molecular mass standards for SDS-
PAGE were from Bio-Rad Laboratories Ltd
(California, USA).
Ostriches
Two female healthy adult ostriches
(Struthio camelus) were obtained from a lo-
cal ostrich farm (Villa de Cura town, Aragua
state, República Bolivariana de Venezuela).
They were housed under standard environ-
ment (humidity, lighting and temperature)
and fed ad libitum with standard ostrich diet
and potable water (Fig. 1).
Venom
A pool of venoms from common rat-
tlesnake (Crotalus durissus cumanensis)
(0.15 mg/mL), Uracoan rattlesnake (Crota-
lus vegrandis) (0.03 mg/mL), Guayana rat-
miento de los caballos desde el punto de vista de infraestructura, alimenta-
ción y atención veterinaria, en los que el costo puede llegar a los 100 USD
por día, frente a los 146 USD por mes de mantenimiento de la producción
de aves. Estos resultados abren un campo terapéutico, para la fabricación
de otros antivenenos contra un amplio espectro de toxinas y también como
probables herramientas de diagnóstico.
Received: 03-08-2021 Accepted: 04-11-2021
60 Bello et al.
Investigación Clínica 63(1): 2022
tlesnake (Crotalus durissus ruruima) (0.02
mg/mL) and black rattlesnake (Crotalus pi-
fanorum) (0.012mg/mL) were obtained by
milking the snakes and then crystallized un-
der vacuum in a desiccator containing CaCl2
as a desiccant and maintained at 4°C until
use (Fig. 1).
Ethical statement
Skilled staff prepared all the experi-
mental methods relating to the use of live
animals. These methods were permitted by
the Institute of Anatomy Ethical Committee
of the Universidad Central de Venezuela un-
der assurance number (Protocol N° 190619)
and followed the norms obtained from the
Guidelines for the Care and Use of Labora-
tory Animals, published by the USA National
Institute of Health 4.
Immunization procedure
Two female ostriches were injected in-
tramuscularly intro the bird’s anterior thigh
muscles on day 0 with the Crot/pool of the
Venezuelan rattlesnake venoms (1µg/kg
body weight) emulsified with an equivalent
volume of complete Freund’s adjuvant. The
primary booster dose was administered two
weeks later in an incomplete Freund’s ad-
juvant. Successively, the second and third
boosters emulsified with an equivalent vol-
ume of incomplete Freund’s adjuvant were
administered at 45-day intervals in order to
sustain high antibody titers. Blood was col-
lected through the wing vein, arranged to
obtain the serum. Sera were separated by
centrifugation (1500 G for 15 min). Pre-
immune serum and egg yolk replicas col-
lected from ostriches were used as negative
controls. They were stored in a freezer at
−20°C, until used.
Purification of antibodies from egg yolk
Isolation of IgY from egg yolk was per-
formed with a modified method 5. Briefly,
once the egg shell was opened, the yolk was
softly detached from the white of the egg,
washing it with abundant distilled water, un-
til all the white egg disappeared. Then, the
yolk was punctured with a syringe and all
its contents were extracted and mixed com-
pletely with a five-fold dilution with PBS pH
7.4 and slow addition of caprylic acid (CA),
then the pH was adjusted to 5.0 with 10 M
Fig. 1. (A) Ostriches at bird’s farm, Villa de Cura, Aragua state, Venezuela. (B) Crotalus durissus cumanensis.
(C) Crotalus ruruima. (D) Crotalus pifanorum. (E) Crotalus vegrandis (1).
1
Crotalus snakes envenoming treated with ostrich (Struthio camelus) IgY 61
Vol. 63(1): 57 - 69, 2022
hydrochloric acid. Concisely, the CA was
slowly added dropwise at an approximate
rate of 0.6 mL/min, until a final concentra-
tion of 6% (v/v) was obtained.
After the first step of the process, the
sample was filtered through a 15 µm and
then 0.45 µm filter.
The preparation was kept to room tem-
perature, and afterward ammonium sulfate
at 30% (W/V) concentration was added,
keeping it under constant stirring for one
hour at room temperature and then filtered
through a 2-µm filter. In order to eliminate
the ammonium sulfate, a tangential filtra-
tion process was applied using a cassette
of 30 kDa. The sample was resuspended in
saline solution and kept under stirring for
one hour- Subsequently, filtered through a
2-µm filter to remove remaining solids and
a diafiltration process was started until
eight diafiltration volumes were completed.
When the ammonium sulfate was removed,
the washed sediment was dissolved in 200
mL saline pH 6.3.
Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) of IgY
Purified IgY under non-reduced and re-
duced conditions were electrophoresed with
a MINIPROTEAN II (BioRad, USA) cham-
ber. SDS-PAGE was performed using 12%
gels. Wide range molecular weight markers
(Bio-Rad) were run in parallel and gels were
stained with Comassie blue (National Diag-
nostic, USA).
Determination of antibody titers by an
indirect ELISA
The immunoglobulins titers in serum
and egg yolk of immunized ostriches were
tested by enzyme-linked immunosorbent
assay (ELISA). Titer was considered as the
concentration of an antibody, as determined
by finding the highest dilution at which it
was still able to cause recognition of the
antigen. The uncomplicated way to do this
is as follows: selecting the highest respond-
ing serum and another that shows low re-
sponse. Do readings for serial dilutions as we
have done (Fig. 3). Looking for one dilution
were both sera are in the steepest part of
the curve, are clearly different (generally a
1:1000 – 1:4000 dilutions will do it) and the
OD450nm of the most responding serum is
nearly 1.0. Then it is possible to define the
titer as the OD450nm for each serum at the
dilution obtained before.
All ELISA incubations were carried out
at 24-26°C. Briefly, aliquots (100 µL) of the
Crot/pool venom (1 µg/mL PBS) were pi-
petted into the wells of the micro-titration
plates in overlay phosphate buffer saline
(PBS) pH 7.4 that were protected with saran
wrap and stored overnight at 4°C. The wells
content was aspirated, and washed three
times with washing buffer (PBS, pH 7.4 con-
taining 0.05% Tween-20), the wells were then
overflowed with blocking buffer (skimmed
milk 2% in PBS-T) and left for one hour. After
the aspiration of blocking buffer, the ostrich
sera or purified IgY immunoglobulins sam-
ples were diluted properly in blocking buffer
and 100 µL added to the wells before incu-
bating at 37°C for one hour. Later, the plates
were washed three times with washing buffer
and incubated with goat anti-avian (includ-
ed anti-ostrich) IgY peroxidase (1:10.000)
at 37°C for one hour. The contents of the
wells were subsequently aspirated, the wells
washed three times with PBS-0.05% Tween
20 (PBS-TW), and 100 µL of peroxidase sub-
strate (TMB)(Vector Lab, USA) was added
to each well. The plates were maintained in
the dark, at room temperature for 20 min
for the progress of dye. The reaction was
stopped with 50 µL of sulfuric acid 1 M. The
absorbance of solutions at X = 450 nm was
determined after the addition of substrate
by an automatic ELISA reader.
Immunoblot analysis
Recognition of IgY antibodies was per-
formed by western blot according to the
modified method 6 (n=3). Briefly, to deter-
mine the specificity of the immunoglobulins
against Crot/pool snake venoms, the anti-
62 Bello et al.
Investigación Clínica 63(1): 2022
bodies were tested with a total of six venoms
Crotalus durissus cumanensis, Crotalus veg-
randis, Crotalus durissus ruruima, and Cro-
talus pifanorum venoms.
These venoms were electrophoresed on
a 10% SDS gel using a Mini-Protean II system
at 150V (Bio-Rad PowerPac Basic) for one
hour. Then, were transferred onto a 0.2 µm
nitrocellulose membrane (Millipore) using
a Trans Blot SD system at 100 mA for one
hour. After blocking the membrane for one
hour at room temperature with 5% skimmed
dry milk in PBS buffer pH 7.4 containing
0.05% (w/v) Tween 20, the nitrocellulose
membrane was incubated under stirring for
one hour with anti-Crot/pool ostrich IgY an-
tivenom diluted to 1:1000 in PBS-Tween 20.
After the rinses, the secondary antibody goat
anti-avian IgY (coupled to horseradish perox-
idase) diluted 1:20000 in PBS-Tween 20 was
complemented. Finally, blots electrophoret-
ic bands identified by Crot/pool ostrich IgY
antivenom were colorimetric visualized us-
ing the peroxidase substrate (TMB), and the
image was analyzed.
Lethality Dose (LD50)
Five groups of five NIH female mice
(Mus musculus) for Crot/pool venom were
maintained in plastic boxes (Tecniplast, Ita-
ly) and observed throughout the quarantine
period and experiments. The endpoint of le-
thality of the mice was established after 48
hr. The venom was suspended in 0.85% saline
at the maximum test dose per mouse. Serial
dilutions of 2-fold using saline solution were
prepared to obtain four extra concentra-
tions. All solutions throughout the experi-
ment were kept at 0°C and warmed to 37°C
before being injected into mice. The lethal
toxicity was determined by injecting 0.2 mL
of venom (containing dosages ranging be-
tween 38.0 to 11.6 µg/mouse) into the peri-
toneum of 18–20 g female NIH mice. The in-
jections were dispensed using a 1-mL syringe
fitted with a 25-gauge, 0.5-inch needle. Sa-
line as normal controls were used. The lethal
dose fifty (LD50) was calculated following the
Spearman-Kärber (n = 3 ± SD) method 7.
The estimated LD50 was then used for testing
median effective dose fifty (ED50/2 LD50).
Antivenom neutralization test: median
effective dose fifty (ED50/2 LD50) assays of
yielded antibodies (anti-Crot/pool ostrich
IgY antivenom neutralizing lethal toxic
activity of Crot/pool venom)
The median effective dose value (ED50)
of the anti-Crot/pool ostrich IgY antivenom
from ostrich egg yolk was measured for analy-
sis of quantitative and categorical data, with
the aid of the Prism 8 program (Graphpad,
USA). Five groups of five female NIH mice
(18–20 g) were confronted with a combina-
tion of serial dilutions of a certain amount of
anti-Crot/pool venoms (1.488, 1.395, 1.321,
1.145, 0.843), containing constant concen-
tration of Crot/pool venom (33 µg). 2LD50:
(LD50=16.5 µg/mouse x 2 = 33 µg venom/20
g mouse). The Ostrich IgY anti-Crot/pool
venom/ Crot/pool venom combinations were
pre-incubated for 30 min at 37°C, then was in-
travenously injected into mice for each dose.
Negative control mice were injected with two
LD50 of venom alone. The neutralizing poten-
cy reproduces the ratio of mL of anti-Crot/
pool venom /mg of Crot/pool venom or mg of
antivenom/mg of venom. The control group
was also injected with venom pre-incubated
with normal ostrich serum.
RESULTS
Immune response
Two female ostriches were immunized
as described in Materials and Methods. De-
tectable specific IgY anti-venom respons-
es were not observed in sera until 15 days
from the initial dose, by the time of the first
booster-dose. This secondary response was
sustained thereafter by successive booster
injections given at 45-days pauses.
IgY purification
At a pH of 5-6 most of the immunoglob-
ulins were recovered and the caprylic acid
Crotalus snakes envenoming treated with ostrich (Struthio camelus) IgY 63
Vol. 63(1): 57 - 69, 2022
precipitation leads to a maximum recovery
of IgY, with minimum contaminating pro-
teins. After ammonium sulfate purification,
the obtained sample under reduction con-
ditions gave two mains electrophoretic IgY
bands of 65 and 20 kDa. Otherwise, under
non-reducing conditions a IgY single band of
175 kDa was observed (Fig. 2). The average
recovery of IgY from a single egg yolk was ~
3800 mg (N=5).
Immune-specific recognition of crotalic
venom pool by IgY
The anti- Crot/pool venom-specific ac-
tivity of IgY in partially purified preparations
was assayed by a home-designed indirect
ELISA as described in Materials and Meth-
ods. The purification procedure resulted in
venom-specific IgY recognition of Crot/pool
venoms (Fig. 3). Microtiter plates with pre-
immune serum showed no binding.
Fig. 2. IgY tested under native and reduction conditions. (1) Molecular mass markers. (2) IgY (native condi-
tions); (3) Under reducing conditions HC: Heavy chain; DHC: Detritus heavy chain; LC: Light chain;
VH: Variable fraction of heavy chain; VL: Portion variable light chain; CL: Constant fraction of light
chain.
Fig. 3. ELISA immuno-specific recognition of IgY. The anti- Crot/pool venom-specific activity of IgY showed
that final product (rhombus) and final product dialyzed (square) resulted in the venom-specific IgY
recognition of Crot/pool venoms. The pre-immune serum (triangle) was negative.
64 Bello et al.
Investigación Clínica 63(1): 2022
Specificity of Crot/pool antivenom (IgY)
to Crotalus venoms via Western blot
The identity of the Crot/pool venom pro-
teins was confirmed with the Crot/pool antive-
nom (IgY) by Western-blot, identifying most of
the fraction venoms used in the present work
(Fig. 4). As a reference, the polyvalent antive-
nom of equine origin produced by BIOTECFAR
C.A (Caracas, Venezuela) was used.
Antivenom effective dose (ED50)
In order to estimate the ED50 of the final
Crot/pool antivenom (IgY), different amounts
of this antivenom were preincubated with 2LD50
(33 µg) of a Crot/venom pool, as described in
Materials and Methods. An ED50 of 19.66 mg
was calculated for the Crot/pool antivenom, as
the minimum amount of purified IgY prepara-
tion able to protect 50% of the mice popula-
tion. There were no survivals in the control
group (Table 1, Fig. 5).
DISCUSSION
Snakebite accidents, categorized as
a neglected tropical disease by the World
Health Organization (WHO) is responsible
for nearly 50.000 deaths annually, mostly in
Third World countries 8.
In the current work specific anti-Crota-
lus snake venoms antibodies were obtained
by an immunization schedule in female os-
triches (Struthio camelus). The eggs from
bird species have demonstrated being a de-
sirable basis for the production of antibod-
ies, without invasive methods, which present
a predominant class of IgY immunoglobulin
3, 9,10. This IgY has been used in diagnosis,
research, and immunotherapy 11-13. Further-
more, bird’s immunoglobulins production
poses several benefits over mammalian an-
tibodies with respect to the antigenic speci-
ficity and low manufacturing expenses 3,12. It
was possible to obtain about 2-4 g of IgY per
ostrich egg. Hence, almost 400 g of IgY can
be purified from only one ostrich per year.
For that reason, ostrich eggs could repre-
sent an exceptional source of immunoglobu-
lins for antivenom production.
A great amount of cross-reactive and
neutralizing antibodies (IgY) were produced
in the egg yolk of ostriches (Struthio cam-
elus) by immunizing with the venom of four
Crotalus (Crot/pool) using a simple and
Fig. 4. Western blot. (A) Crot/pool venom+ PAOS (Biotecfar C.A, Venezuela); (B) Crot/pool venom+ immu-
nized ostrich IgY; (C) Negative control (Non-immunized ostrich IgY+PBS).
Crotalus snakes envenoming treated with ostrich (Struthio camelus) IgY 65
Vol. 63(1): 57 - 69, 2022
Table 1
Determination of the survive percentage of mice after the injection of 2LD50 of Crot/pool venom with different
concentrations of ostrich IgY. Evaluation of the neutralizing capacity of anti-crotalic IgY antibodies.
LD50
16.5
(µg/mouse)
Concentration
(mg/mL)
Vol.
(mL)
Mx
Amount of
proteins
(mg)
Vol.
(mL)
Venom
Amount of
injected
venom (µg)
Vol.
(mL)
Saline
solution
Final Vol.
(mL)
Inoculated
animals Dead Alive Accumulated
Deaths
Accumulated
Alive
% survival
18.6
1.655 30.78 0.330
33
0.015 2 5 0 5 0 13 100.00
1.335 24.83
0.165
0 1.5 5 1 4 1 8 88.89
1.125 20.93 0.375 1.5 5 2 3 3 4 57.14
0.750 13.95 0.750 1.5 5 4 1 7 1 12.50
0.375 6.98 1.125 1.5 5 5 0 12 0 0.00
0.190 3.53 1.310 1.5 5 5 0
LD50: Lethal dose fifty; Vol: Volume.
66 Bello et al.
Investigación Clínica 63(1): 2022
inexpensive method. Knowledge of venom
variations permits the selection of suitable
specimens for production of more effective
antivenoms and biological substances.
The anti- Crot/pool venom immuno-
globulins were carried out from egg yolk by
the McLaren RD et al. 5 method and given a
single pure electrophoretic IgY band of 174
kDa (native conditions) and 65/20 kDa (un-
der reduced conditions) in the SDS-PAGE.
Neutralization experiments demon-
strated a high neutralization capacity of the
anti- Crot/pool preparation, as a preincu-
bated mixture of both purified antivenom
(19.66 mg) with two LD50 dose of Crot/pool
venom (33 µg) protected 50% of the mice.
It has been showed since the early nine-
ties (1990) that chicken egg yolk and their
IgY immunoglobulins were able to neutral-
ize scorpion and rattlesnake venoms, con-
firmed by in vivo experiments performed in
rodents 13. Comparing hens with ostriches,
the ostrich is one of the most primitive liv-
ing avian suggesting that the diverse fea-
tures of the bird Ig genes appeared very
early during the divergence of the avian spe-
cies and are thus common by most, if not
all, bird’s species 14.
Antibodies are competent of explicitly
recognizing a wide diversity of antigens with
different affinities. Affinity, simultaneously
with avidity is closely related to sensitivity,
which is an experimentally measurable value
in terms of antibody titer. Affinity is the con-
centration of the antigen that is needed to
occupy the binding sites, of half of the anti-
body molecules present in an antibody solu-
tion, while avidity is the universal summation
of the affinities of various antibodies (biva-
lent, multivalent and of different isotypes)
fixed to all places to all available epitopes,
considering conformational and valence as-
pects of the antibody 15. Authors 3 have devel-
oped successful anti-coral snake venom IgY
antibodies, which were carried out in chick-
en egg yolks and their neutralizing action
was similarly presented in mice by in vivo
counteraction experiments. These antive-
nom immunoglobulins neutralized the toxic
and lethal consequences of venom and, ac-
cordingly, could function to treat coral snake
envenomed victims. Similarly, authors 16 have
also produced hen antibodies against Scolo-
pendra gigantea toxins with high neutraliza-
tion titers and antivenom for the treatment
of scolopendrism 17.
Fig.5. Curve of Log doses of mg of protein with the percentage of survival animals. An ED50 of 19.66 mg Crot/
pool antivenom (IgY) was calculated from the represented data as the mass of IgY that was able to
protect at least 50% of the mice population against a 2LD50 (33 µg) challenge of Crot/pool venom. In
the control group there were no survivals. (%): percentage. (Log): logarithm.
Crotalus snakes envenoming treated with ostrich (Struthio camelus) IgY 67
Vol. 63(1): 57 - 69, 2022
The present experimental work refers
to the production of anti-(Crot/pool) anti-
venom in ostrich egg yolk and its ability in
deactivating the lethal consequences of the
above mentioned Crotalus venoms. Immu-
nization of ostriches with Crot/pool venom
provoked a characteristic primary humoral
response of low antibody titer in the ostrich
sera and the egg yolks at 15 days, followed
for a higher secondary response. The immu-
noglobulins titres amplified after the second
booster and the intensities were sustained
by continuing boosters. Ostrich eggs kept at
5°C during a year exhibited no substantial
reduction in the antibody titers.
The caprylic acid 18, 19 method showed
that under controlled pH conditions, at
a constricted pH range of 5.3–6.3 and low
ionic strength of acidified water simplified
the separation of IgY, after the yolk lipids
aggregation, producing a clear IgY enriched
supernatant, which was confirmed by SDS-
PAGE analysis. This technique has been used
for experimental purposes 18, but actually
is used in the production of horse antiven-
oms 19, with novel fractionation approaches
for antivenom production with the purpose
of achieving antivenoms of higher purity,
which would stimulate less allergic reactions
in snake bitten patients treated with this
product.
In the current work, it has been es-
tablished by an immunoblot and/or ELISA
assays that the anti-(Crot/pool) antivenom
IgY recognized and responded to Crot/pool
venom proteins. Immunoblot analysis re-
vealed not only the specific binding of the
antivenom but also dose-dependent blocking
of antivenom by venom proteins.
The outcomes of inhibition studies
show a specific neutralizing capacity of ven-
om activity in the experimental anti-(Crot/
pool) IgY antivenom. This ending activity
was regularly dose dependent, presenting
ample inhibition at a concentration of 2LD50
(33µg) of Crot/pool venom, being indicative
of specific binding of the IgY antibodies to
venom proteins to which they were devel-
oped and their capacity to block the lethal
effects of Crot/pool venoms. These types of
immuno-neutralization help reverse toxicity
and define the kinetics of toxins and anti-
bodies.
Until now, traditional treatment of
snakebite accidents is based on the use of
antivenoms from horse’s origin. Neverthe-
less, equine serum in theory could activate
complement cascade and initiate acute hy-
persensitivity reactions in patients formerly
sensitized to horse serum proteins 20. The
immunoglobulin IgY has the capacity of
eliminating this possible side effect since it
does not react as the mammalian IgG per-
forms and it does not activate the mamma-
lian complement factors 9. For that reason,
the horse serum mammalian IgG activating
mammalian complement factors 20 does not
permit physicians to give out much larger
doses of horse antivenom.
Regarding recent developments of
chicken antivenoms, Latin American authors
17 have characterized IgY antivenoms capable
of neutralizing the lethal activity of B. alter-
natus snake venom, at a preclinical level. An
antivenom, as an alternative to the conven-
tional antivenom production with egg yolk
antibodies (IgY-technology) was proposed.
Similarly, to the results presented in the cur-
rent work, antivenom efficacy assays were
carried out by them and after successive im-
munizations, levels of specific IgY reached a
maximum that was maintained throughout
the observation period; IgY antivenoms ob-
tained after several immunizations neutral-
ized 35.65 µg of B. alternatus venom per mg
of antivenom. Other authors 21 proposed that
birds were excellent hosts for the produc-
tion of neutralization antibodies at low cost.
These antibodies could be applied in the de-
velopment of diagnostic kits or as an alterna-
tive for snakebite envenomation handling in
the immediate future.
In conclusion, the specificity and spe-
cific activity of the antibody were scrutinized
by western blotting and confirmed the pres-
ence of highly specific antibodies to Crot/
68 Bello et al.
Investigación Clínica 63(1): 2022
pool venoms in the treated ostrich egg yolk.
Ostrich’s antivenom can represent an excel-
lent alternative for producing high amounts
of antivenoms at very low costs 22. Thus, they
could be a very good option to treat these
accidents in countries with low economic
resources where the ophitoxemia is a collec-
tive health problem. Therefore, the cleanli-
ness, efficiency, and simplicity of producing
antivenoms in ostriches, and the inability
of these antibodies (IgY) to bind to the hu-
man complement formulates an interesting
alternative to other antivenoms produced in
mammals. These findings point out that os-
trich egg antibody can be helpful as a thera-
peutic instrument to treat snakebites in hu-
mans, cattle and domestic animals.
In addition, these results open a thera-
peutic field, for the manufacturing of other
antivenoms against the broad spectrum of
toxins and also as a probable diagnostic
tool.
ACKNOWLEDGEMENTS
The authors are grateful to Lic. Rosa
Gutierrez Sánchez and her husband Juan C.
Da Silva, owners of the ostrich’s farm “Inver-
siones en Avestruces Rosa Gutierrez F.P” for
their generous help, managing the animal’s
upkeep. We would like to thank the helpful
commentaries from two anonymous refer-
ees, which allowed us to improve the manu-
script.
Declaration of conflict of interest
The authors pronounce that they have no
known competing financial interests or per-
sonal associations that could give the idea to
influence the work described in this work.
Funding
This work was funded by Biotecfar C.A
(Grant Ostrich #1), Facultad de Farmacia,
Universidad Central de Venezuela, Caracas,
República Bolivariana de Venezuela.
Authors’ ORCID numbers
Carlos Bello (CB)
0000-0002- 5689-9284
Fática Torrico (FT):
0000-0003-3388-8299
Mariana Cepeda (MC):
0000-00025396-8483
Miguel A. López (MAL):
0000-0002-6162-711X
Alexis Rodriguez-Acosta (ARA):
0000-0003-1234-7522
Juan Carlos Jimenez (JCJ):
0000-0002-1554-4292
Authors' contribution
MAL, FT and ARA envisioned and
planned research; CB, JCJ, MVC and ARA
carried out experiments; CB, FT, JCJ and
ARA analysed data; CB, FT, JCJ and ARA elu-
cidated results of experiments; CB and ARA
drafted manuscript; MAL, CB, FT, JCJ and
ARA edited and revised manuscript; MAL,
CB, FT, JCJ, MVC and ARA accepted final
version of manuscript.
REFERENCES
1. Rengifo C, Rodríguez-Acosta A. Serpien-
tes, Veneno y Tratamiento Médico en Ve-
nezuela. Caracas: Universidad Central de
Venezuela, 2019; 1-272.
2. Aguilar I, Sánchez EE, Girón ME, Estrella
A, Guerrero B. Rodríguez-Acosta A. Co-
ral snake antivenom produced in chickens
(Gallus domesticus). Rev Inst Med Trop Sao
Paulo 2014; 56: 61-66.
3. Almeida CM, Kanashiro MM, Rangel-Filho
FB, Mata MF, Kipnis TL, da Silva WD. De-
velopment of snake antivenom antibodies
in chickens and their purification from
yolk. Vet Rec 1998; 143: 579–584.
4. NIH, Principles of laboratory animal care.
National Institute of Health of United Sta-
tes of America, Pub. 85-23, Maryland; 1985;
1–112.
Crotalus snakes envenoming treated with ostrich (Struthio camelus) IgY 69
Vol. 63(1): 57 - 69, 2022
5. McLaren RD, Prosser CG, Grieve RC, Bo-
rissenko M. The use of caprylic acid for
the extraction of the immunoglobulin frac-
tion from egg yolk of chickens immunised
with ovine alpha-lactalbumin. J Immunol
Methods 1994; 177:175-184.
6. Towbin H, Stachelin T, Gordon J. Electro-
phoretic transfer of proteins from polyac-
rylamide gels to nitrocellulose sheets: pro-
cedure and some applications. Proc. Natl
Acad Sci USA 1979; 76: 4350–4354.
7. Spearman- Kärber R. Alternative methods
of analysis for quantal responses. In: Finney
D, editor. Statistical method in biological
assay. London, Charles Griffin; 1978; 1– 78.
8. Bagcchi S. Experts call for snakebite to be
re-established as a neglected tropical disea-
se. BMJ. 2015; 351: h5313.
9. Larsson A, Balow RM, Lindahl TL, Fors-
berg PO. Chicken antibodies: taking advan-
tage of evolution. A Rev Poultry Sci 1993;
72: 1807-1812.
10. Adachi K, Handharyani E, Sari DK, Taka-
ma K, Fukuda K, Endo I, Yamamoto R,
Sawa M, Tanaka M, Konishi I, Tsukamoto
Y. Development of neutralization antibo-
dies against highly pathogenic H5N1 avian
influenza virus using ostrich (Struthio ca-
melus) yolk. Mol Med Rep 2008;1:203–209.
11. Larsson A, Mellstedt H. Chicken antibo-
dies: a tool to avoid interference by human
anti-mouse antibodies in ELISA after in
vivo treatment with murine monoclonal
antibodies. Hybridoma 1992; 11: 33–39.
12. Schade R, Calzado EG, Sarmiento R,
Chacana PA, Porankiewicz-Asplund J,
Terzolo HR. Chicken egg yolk antibodies
(IgY-technology): a review of progress in
production and use in research and human
and veterinary medicine. Altern Lab Anim
2005;33:129-154.
13. Thallay BS, Carroll SB. Rattle snake and
scorpion antivenoms from the egg yolks of
immunized hens. Biotechniques (NY) 1990;
8: 934–938.
14. Huang T, Zhang M, Wei Z, Wang P, Sun Y,
Hu X, Ren L, Meng Q, Zhang R, Guo Y,
Hammarstrom L, Li N, Zhao Y. Analysis of
immunoglobulin transcripts in the ostrich
(Struthio camelus), a primitive avian spe-
cies. PLoS ONE 2012; 7: e34346.
15. Morimoto J, Sarkar M, Kenrick S, Koda-
dek T. Dextran as a generally applicable
multivalent scaffold for improving immu-
noglobulin-binding affinities of peptide and
peptidomimetic ligands. Bioconjug Chem
2014; 25:14791491.
16. Parrilla P, Navarrete LF, Girón M.E, Agui-
lar I, Rodríguez-Acosta A. Use of chicken
egg yolk-derived immunoglobulin against
Scolopendra venom as an alternative to
treat scolopendrism. Rev Cient FCV-LUZ
2008; 18: 385-392.
17. Leiva CL, Cangelosi A, Mariconda V, Fa-
race M, Geoghegan P, Brero L, Fernán-
dez-Miyakawa M, Chacana P. IgY-based
antivenom against Bothrops alternatus:
Production and neutralization efficacy. To-
xicon 2019; 163: 84-92.
18. Dos Santos MC, D’imperio-Lima MR, Fur-
tado GC, Colletto GM, Kipnis TL, Dias da
Silva W. Purification of F(ab’)2 anti-snake
venom by caprylic acid: a fast method for
obtaining IgG fragments with large neutra-
lization activity, purity and yield. Toxicon
1989; 27: 297-303.
19. Rojas G, Jimenez JM, Gutierrez JM. Ca-
prylic acid fractionation of hyper immune
horse plasma: description of a simple pro-
cedure for antivenom production. Toxicon
1994; 32: 351-363.
20. Sutherland SK. Serum reactions. An analy-
sis of commercial antivenoms and the pos-
sible role of anticomplementary activity in
de-novo reactions to antivenoms and anti-
toxins. Med J Aust. 1977; 1: 613–615.
21. Lee CH, Liu CI, Leu SJ, Lee YC, Chiang
JR, Chiang LC, Mao YC, Tsai BY, Hung
CS, Chen CC, Yang YY. Chicken antibodies
against venom proteins of Trimeresurus ste-
jnegeri in Taiwan. J Venom Anim Toxins Incl
Trop Dis 2020; 26: e20200056.
22. Carbajo E. Produccion de avestruces: Una
industria ya establecida. Rev Cien Vet 2007;
23: 3-5.